换一批Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
第一作者：
Martin B,Leon
第一单位：
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA. mleon@crf.org
作者：
医学主题词
老年人(Aged);血管成形术, 气囊, 冠状动脉(Angioplasty, Balloon, Coronary);心血管药物(Cardiovascular Agents);缩窄, 病理性(Constriction, Pathologic);冠状血管造影术(Coronary Angiography);冠状动脉疾病(Coronary Artery Disease);费用效益分析(Cost-Benefit Analysis);药物洗脱支架(Drug-Eluting Stents);女(雌)性(Female);卫生保健费用(Health Care Costs);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);模型, 经济学(Models, Economic);心肌梗死(Myocardial Infarction);紫杉酚(Paclitaxel);前瞻性研究(Prospective Studies);假体设计(Prosthesis Design);生活质量(Quality of Life);质量校正寿命(Quality-Adjusted Life Years);危险性评估(Risk Assessment);单盲法(Single-Blind Method);西罗莫司(Sirolimus);时间因素(Time Factors);治疗结果(Treatment Outcome);美国(United States)
DOI
10.1016/j.jcin.2009.10.008
PMID
20129547
发布时间
2016-11-25
- 浏览14
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
